Gerburg Wulf
Harvard University
H-index: 53
North America-United States
Top articles of Gerburg Wulf
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.
medRxiv
2024
Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+ …
Cancer Research
2024/5/2
Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen …
Cancer Research
2024/5/2
Gerburg Wulf
H-Index: 32
Abstract CT042: NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with …
Cancer Research
2024/4/5
Mechanisms of succinate-mediated drug resistance in ER+ breast cancer
Cancer Research
2024/3/22
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
Cancer Discovery
2024/2/8
Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report
Case Reports in Oncology
2024/1/3
Gerburg Wulf
H-Index: 32
RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
Nature Communications
2023/3/13
Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
2023/12/11
Abstract B039: Effect of cross-sex testosterone therapy on Pik3ca-driven breast cancer incidence in mice
Cancer Epidemiology, Biomarkers & Prevention
2023/12/1
Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report
Case Reports in Oncology
2023/3/7
Abstract B037: Effect of cross-sex estrogen therapy on olaparib treatment in mice
Cancer Epidemiology, Biomarkers & Prevention
2023/12/1
Abstract PD11-05: PD11-05 Gut microbiome signatures correlate with overall survival among patients receiving eribulin with or without pembrolizumab for hormone receptor …
Cancer Research
2023/3/1
Abstract PR009: Effect of testosterone therapy on quantitative breast lobular atrophy in transmasculine individuals
Cancer Epidemiology, Biomarkers & Prevention
2023/12/1
Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers
Cancer Research
2023/3/1
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline …
JCO Precision Oncology
2023/11
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer (041)
Gynecologic Oncology
2023/9/1
Abstract P2-23-01: Patient-derived xenografts allow deconvolution of single agent and combination chemotherapy responses in triple-negative breast cancer
Cancer Research
2023/3/1
Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms
Journal of Biological Chemistry
2023/8/1
Naama Kanarek
H-Index: 11
Gerburg Wulf
H-Index: 32
PARP-inhibitors Improve Progression-Free Survival in Breast Cancer Patients with Previous Platinum Exposure–A Systematic Review and Meta-Analysis
2023/6/26
Gerburg Wulf
H-Index: 32
Felipe Batalini
H-Index: 5
Co-Authors
